Cypress Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Cypress Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$857K	Sell	14,865 -461	-3%	-$26.5K	0.35%	39
2026 Q1	$930K	Buy	15,326 +8,446	+123%	+$492K	0.5%	38
2025 Q4	$371K	Sell	6,880 -10,116	-60%	-$487K	0.2%	57
2025 Q3	$767K	Sell	16,996 -886	-5%	-$41.4K	0.44%	44
2025 Q2	$828K	Buy	17,882 +37	+0.2%	+$1.82K	0.52%	40
2025 Q1	$1.09M	Sell	17,845 -22	-0.1%	-$1.28K	0.76%	25
2024 Q4	$1.01M	Buy	+17,867	New	+$998K	0.79%	26

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cypress Capital Advisors's BMY Position: Q2 2026 in Review

Cypress Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 3% in Q2 2026, selling an estimated $26.5K and leaving 14,865 shares worth $857K. The position accounts for 0.35% of the portfolio, ranked #39.

Cypress Capital Advisors first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.09M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Cypress Capital Advisors held 14,865 shares of Bristol-Myers Squibb worth $857K as of Q2 2026.
Cypress Capital Advisors sold 461 Bristol-Myers Squibb shares in Q2 2026, an estimated $26.5K.
Bristol-Myers Squibb made up 0.35% of Cypress Capital Advisors's portfolio in Q2 2026, its #39 holding.
Cypress Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
Cypress Capital Advisors's Bristol-Myers Squibb position peaked at $1.09M in Q1 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Cypress Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.